Minipig Critical-Size Defect Model - Cell D by malj

VIEWS: 91 PAGES: 18

									                 Dr Mark Chong
National University of Singapore
          Dept of Obstetrics and
                   Gynaecology
     nd
2        most transplanted tissue
  • 1 million cases annually in US alone

 Current     treatment:
  • Autograft: Site morbidity
  • Allograft: Donor shortage, immune rejection

 Solution:    Tissue Engineering
 Resorbable  scaffolds + osteogenic cells
 Mature in bioreactor à TisXell System
 Note:
  • Function of bone is primarily structural
  • à low hanging fruit



                 Mesencymal
                  stem cells
                    (MSC)
          Day 0   Day 14              Day 28
TisXell




                    Increased
                                     Increased
                       cellular
                                  mineralisation
                  proliferation
          Day 0   Day 14              Day 28
TisXell




                     Increased
                  Increased
                                     Increased
                       cellular
                    viability
                                  mineralisation
                  proliferation




                         Live
                        Dead
TisXell
   Created 7 mm defect
   Press-fit 8 mm graft
        S
    S
                    S




S
            S
                S
   TisXell stimulates bone formation
    • 5.7 x more mineralisation than static
   TisXell generated bone grafts are highly
    efficacious
    • Rapid healing of fracture within 3 months vs non-
     union
 Minipig model
 Larger volume, anticipate issues of
  vascularisation
 Introduce endothelial progenitor cells
  (EPC) into cellular mix

       Mesencymal           Endothelial
        stem cells          Progenitor
          (MSC)             Cells (EPC)
      à TisXell
       supports
       co-culture
       of different
MSC    cell types
EPC
 18mm segmental defect in tibia
 Monitor over 12 months:
  • X-ray, CT, angiography
                fMSC-EPC




    MSC
1 mth   3 mth   1 mth
   MSC          fMSC-EPC




1 mth   3 mth     1 mth
 6 pigs implanted with TisXell cultured
 TEBG
 All pigs survived; no adverse reaction
 Mineralisation and bridging evident at 3
 mths in MSC group; 1 mth in fMSC-EPC
 group
 Studies to continue for long-term safety
 data (12 months)
 TisXell provides a controlled and
 conducive environment for generating
 TEBG implant
 Potent osteo-stimulatory cues
 Efficacy demonstrated in rat model
 Potentially faster bone regeneration and
 vascularisation in minipig model
 Preparatory work with clinicians for
 Clinical Phase I trial

								
To top